Printer Friendly

Study Shows Vardenafil Improved Erectile Function in Older Men.

Health & Medical Editors

WEST HAVEN, Conn.--(BW HealthWire)--May 9, 2001


Results Presented to the American Geriatrics Society Show Improved

Scores for Older Men Similar to Those for Younger Men

Men over age 65 experienced improved erections after taking vardenafil, Bayer's investigational treatment to improve erectile function. The results presented this week at the annual American Geriatrics Society meeting in Chicago also showed vardenafil was generally well tolerated.

"Vardenafil enhanced erectile function in older men," said Christopher P. Steidle, M.D., a clinical associate professor of urology at Indiana University School of Medicine and co-author of the analysis. "This is an important finding because men over age 65 are more likely to suffer from impaired erectile function and also are more difficult to treat."

According to the Massachusetts Males Aging Study, the prevalence of erectile dysfunction increases dramatically with age. In fact, according to the study, 57 percent of men in the U.S. ages 60-69 experience some type of ED(1).

The latest analysis of the large Phase II vardenafil study compared 65 older men (> 65 years) and 134 younger men (18 to 45 years). All had reported mild to severe impaired erectile function for more than six months. The patients were randomized into four groups and were given 5 mg, 10 mg, or 20 mg doses of vardenafil (a phosphodiesterase 5 (PDE-5) inhibitor) or placebo on demand.

The study participants were evaluated using the erectile function domain, part of the International Index of Erectile Function (IIEF), a standard sexual function questionnaire used by urologists. The men answered the questionnaire after a four-week pre-treatment period and again after 12 weeks of treatment. Each answer is assigned a points value, with a maximum of 30 points possible. Anyone scoring between 26 and 30 points is considered to have normal sexual function.

In this study, the average change in scores for patients taking vardenafil was similar among the older and younger age groups. The average improvement for older patients on vardenafil was between 2.5 and 10.3 points, depending on the dose they were given. The average improvement for younger patients on vardenafil was between 7.9 and 8.4 points, depending on dose. In contrast, there was very little improvement in scores for the placebo-treated patients. The average improvement for older patients on placebo was 0.5 points, the average improvement for younger patients on placebo was 1.1 points.

The occurrence of adverse events also was similar in older and younger patients. Those adverse events included headache, nasal congestion, upset stomach, and flushing.

An earlier, separate pharmacokinetic (PK) study evaluated vardenafil clearance in the same age groups. A 40 mg dose was given -- higher than that used in the Phase II trial. Peak levels were reached at a similar time in both older and younger subjects (mean times of 30 minutes and 36 minutes, respectively). Vardenafil took slightly longer to clear from the blood in older men than in younger men. The drug's half-life was six hours for older men and 4.8 hours for younger men.

"This study suggests that vardenafil is cleared from the body in a similar timeframe for older and younger men. That is especially important for older men because you don't want any drug remaining in their bodies longer than needed," said Dr. Steidle.

Last month at the European Association of Urology meeting in Geneva, Switzerland, data was presented showing vardenafil improved erectile function in men regardless of age, cause, or the severity of erectile impairment. In addition, the study showed vardenafil not only improved erections in up to 80 percent of men, but also increased their ability to complete sexual intercourse with ejaculation(2).

Vardenafil is an oral treatment currently under investigation to improve erectile function. Bayer plans to submit a new drug application (NDA) for this compound to the U.S. Food and Drug Administration later this year.

Bayer Committed to Men's Health

Bayer is committed to improving men's health. Bayer Corporation already has established itself as a credible force in men's health with Cipro(R)(a) (ciprofloxacin HCl) to treat chronic bacterial prostatitis. Bayer also is marketing Viadur (TM)(b), the first and only, once-yearly, continuous testosterone suppression therapy to treat symptoms of advanced prostate cancer. Other men's health products include One-A-Day(R) Men's High Potency Multivitamin/Multimineral Supplement, One-A-Day(R) Prostate Health, and Bayer Immuno 1(TM) System Complexed Prostate Specific Antigen (cPSA) -- an assay used to measure prostate-specific antigen levels at a time of diagnosis and to monitor them over time.

Best known for its flagship product, Bayer Aspirin, Bayer Corporation produces a broad range of health care, life sciences, and chemical products that help diagnose and treat diseases, purify water, preserve local landmarks, protect crops, advance automobile safety and durability, and improve people's lives.

Headquartered in Pittsburgh, Bayer Corporation had sales of $10.1 billion in 2000 and is one of Fortune magazine's Most Admired Companies. The company employs 23,200 people. It is a member of the worldwide Bayer Group, a $29 billion international health care and chemicals group based in Leverkusen, Germany. The Bayer Group (BAYG.DE) stock is a component of the DAX, and is listed on multiple foreign exchanges.

(a) View prescribing information for Cipro(R) at

(b) View prescribing information for Viadur(TM) at


1. Feldman H, Goldstein I, Hatzichristou D, Krane R, and McKinlay J.

Impotence and its medical and psychosocial correlates: Results of

the Massachusetts Male Aging Study. Journal of Urology, 1994:


2. Porst H, Rosen R, Padma-Nathan H, Goldstein I, Giuliano F, and the

International Vardenafil study group. "Vardenafil, a new highly

selective PDE-5 inhibitor, improves erectile function irrespective

of the baseline severity and etiology of ED or age of patient."

(Poster presented at EAU, 2001.)
COPYRIGHT 2001 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2001, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Geographic Code:1USA
Date:May 9, 2001
Previous Article:FreeMarkets Announces Agreement With Rio Tinto; Leading Global Mining Company to Leverage FreeMarkets' Online Bidding Technology and Services to...
Next Article:World Gold Council Report States, Gold Derivatives: The Gold Market Impact.

Related Articles

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters